Today, U.S. Secretary of Commerce Penny Pritzker announced the 25 awardees that will receive $10 million under the Economic Development Administration’s (EDA) 2015 Regional Innovation Strategies (RIS) program. The 2015 RIS program is managed by EDA’s Office of Innovation and Entrepreneurship (OIE) and is designed to advance innovation and capacity-building activities in regions across the country through two different competitions: the i6 Challenge and the Seed Fund Support (SFS) Grants competition.
“As the driving force behind the Administration’s focus on entrepreneurship, the Department of Commerce is committed to helping set the conditions for innovators and entrepreneurs to test new ideas, take risks, find financing and customers, and ultimately thrive,” said Secretary Pritzker. “The Regional Innovation Strategies program is critical to ensuring that entrepreneurs have access to the tools they need to move their ideas and inventions from idea to market.”
The Hercules Pinkney Life Sciences Park has been renamed to Pinkney Innovation Complex for Science and Technology at Montgomery College (PIC MC). The new name reflects the Center’s mission of fostering a more innovative workforce.
The Montgomery College Board of Trustees approved the new name which is relevant to today’s economic environment and to the business sectors who partner with the academic programs represented at the park.
LOCATION: Montgomery County Department of Economic Development, 111 Rockville Pike, Suite 800, Rockville, MD 20850
Southern Maryland’s Energetics Technology Center (ETC-MD) announces it is opening Montgomery County’s newest technology business incubator as part of the ETC-MD TechFire incubator network at the former National Labor College located at 10000 New Hampshire Avenue. This incubator is sponsored by the Army Research Labs and is purposed to serve companies interested in commercializing ARL developed technologies although other technology companies will be considered as well. Find out how you can work successfully with the Army Research Lab at this informative session.
Hear from the exciting companies completing the first Relevant Health cohort! This event is currently invite only, but if you would like to find out more and possibly attend please send an email to info@relevanthealth.md
Baltimore health IT startup Protenus Inc. has raised $2.6 million of a $4 million equity funding round, according to documents filed with the federal Securities and Exchange Commission.
CosmosID, the leading genomic big data company focused on microbiome research, outbreak investigations, and infectious disease diagnostics, using next-generation DNA sequencing, announced $6M in Series B funding. The company will expand its engineering capabilities, enhance clinical applications, undertake research and development to improve linkage of the DNA genetic code to actual biological traits (genotype to phenotype), such as antibiotic resistance, and develop new products directed at monitoring, predicting, and preventing disease outbreaks.
GlaxoSmithKline has expanded its alliance with Adaptimmune Therapeutics to accelerate its lead clinical cancer programme toward pivotal trials in synovial sarcoma. The companies signed a strategic collaboration and licensing agreement in June last year for up to five programs, including the lead programme, an affinity enhanced T-cell immunotherapy (GSK3377794) targeting NY-ESO-1, one of the best-characterised and most immunogenic cancer antigens frequently expressed by tumours. GSK can license the programme if it chooses to.
In the blink of an eye, a business world that required only antivirus protection now requires far better solutions to combat sophisticated, determined ‘bad actors’ who want to steal your valuable information. You can’t pick up a newspaper or watch a news program and not read or hear about an important breach. Despite spending at a rate of $100 billion annually, global damages from cybersecurity breaches and attacks are on a trajectory to increase from $500 billion to potentially more than $2 trillion per year.
US President Barack Obama’s plan to get a vast Pacific Rim trade deal through Congress this year is taking flak from the presidential campaign trail, where disdain for the pact appears to be one of the rare unifying themes for almost everyone from Donald Trump to Hillary Clinton.
Mission Therapeutics said Tuesday it raised a 60 million pound ($85.8 million) financing round led by Imperial Innovations Businesses LLP. New investor Woodford Patient Capital Trust Plc took part with follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. U.K.-based Mission Therapeutics is a drug discovery and development company.
Cambridge, Massachusetts-based Spero Therapeutics, a biopharmaceutical company targeting drug resistant bacterial infections, raised $30 million in Series B preferred financing, matching the $30 million Series A round Spero raised in June. Existing Series A investors Atlas Venture, SR One, MRL Ventures, Lundbeckfond Ventures, The Kraft Group and Partners Innovation Fund all returned to participated.
Dictionary.com defines “outlier” as: (1) something that lies outside the main body or group that it is a part of, (2) someone who stands apart from others of his or her group, as by differing behavior, beliefs, or religious practices (Synonyms: nonconformist, maverick, original), (3) Statistics: (a) an observation that is well outside of the expected range of values in a study or experiment, (b) a person whose abilities, achievements, etc., lie outside the range of statistical probability.
Merck has expanded its digital health accelerator programme, opening it up in the first country outside its home territory of Germany. The company has picked Kenya for the new programme, which will run for three months and see it look for three digital health startups to support with equity-free funding of $15,000.
For the past five years until January, a team of federal contractors has been poring over academic journals, news reports and press releases in search of emerging technology that could change the outcome of clinical care.
The team’s goal was to write reports containing lists of topics worth further research from the Department of Health and Human Services. The assessment team surfaced medical products and techniques such as “wearable artificial kidney for managing end-stage renal disease” or “joint-sparing knee implant[s] for treatment of knee osteoarthritis,” according to the team’s report from last year.
A Virginia House panel on Wednesday advanced bills that would allocate about $40 million for grants that some of the state’s most powerful business, education and government interests are touting as a boon to regional economic growth.
The complex nature of cancer and its manifestation strikes fear in the heart of many who receive the diagnosis. Scientists are making incredible strides, however, in both the development of diagnostic techniques and treatments. International Innovation’s Stephanie Spurr speaks with Professor of Cell and Gene Therapy at UCL, Waseem Qasim, and explores how gene editing is contributing to far greater success in this field.
The World Medical Innovation Forum is shaping up as a fantastic showcase of cancer innovation, breakthrough science and thought leadership from across the oncology community. I encourage you to join me at this unrivaled gathering. For a full list of all of the speakers, visit the website at: worldmedicalinnovation.org/speakers
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
